TNSN97073A1 - Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1- piperazinyl)-etyl)-6-chloro-1,3-dihydro-2 h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant - Google Patents

Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1- piperazinyl)-etyl)-6-chloro-1,3-dihydro-2 h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant

Info

Publication number
TNSN97073A1
TNSN97073A1 TNTNSN97073A TNSN97073A TNSN97073A1 TN SN97073 A1 TNSN97073 A1 TN SN97073A1 TN TNSN97073 A TNTNSN97073 A TN TNSN97073A TN SN97073 A TNSN97073 A TN SN97073A TN SN97073 A1 TNSN97073 A1 TN SN97073A1
Authority
TN
Tunisia
Prior art keywords
benzisothiazole
piperazinyl
indole
dihydro
chloro
Prior art date
Application number
TNTNSN97073A
Other languages
English (en)
Inventor
R Busch Frank
A Rose Carol
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN97073A1 publication Critical patent/TNSN97073A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE LE TRIHYDRATE DE MESYLATE DE 5- (2-(4-(1,2 - BENZISOTHIAZOLE- -3- yl) - 1 - PIPERAZINYL) - ETHYL - 6 - CHLORO – 1,3 - DIHYDRO – 2H -INDOLE - 2- ONE. ELLE CONCERNE EGALEMENT UN PROCEDE POUR SA PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LE CONTENANT. APPLICATION : UTILISATION DE CE COMPOSE ET DE CES COMPOSITIONS POUR LE TRAITEMENT D'AFFECTIONS PSYCHOTIQUES.
TNTNSN97073A 1996-05-07 1997-05-06 Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1- piperazinyl)-etyl)-6-chloro-1,3-dihydro-2 h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant TNSN97073A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
TNSN97073A1 true TNSN97073A1 (fr) 2005-03-15

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN97073A TNSN97073A1 (fr) 1996-05-07 1997-05-06 Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1- piperazinyl)-etyl)-6-chloro-1,3-dihydro-2 h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant

Country Status (46)

Country Link
US (1) US6110918A (fr)
EP (1) EP0904273B1 (fr)
JP (1) JP3102896B2 (fr)
KR (1) KR100333214B1 (fr)
CN (1) CN1092658C (fr)
AP (1) AP838A (fr)
AR (1) AR007003A1 (fr)
AT (1) ATE236902T1 (fr)
AU (1) AU730856C (fr)
BG (1) BG63601B1 (fr)
BR (1) BR9708932A (fr)
CA (1) CA2252895C (fr)
CO (1) CO4940465A1 (fr)
CZ (1) CZ289216B6 (fr)
DE (1) DE69720719T2 (fr)
DK (1) DK0904273T3 (fr)
DZ (1) DZ2221A1 (fr)
EA (1) EA001180B1 (fr)
EG (1) EG24401A (fr)
ES (1) ES2192264T3 (fr)
GT (1) GT199700042A (fr)
HK (1) HK1017893A1 (fr)
HN (1) HN1997000040A (fr)
HR (1) HRP970235B1 (fr)
HU (1) HU229057B1 (fr)
ID (1) ID17504A (fr)
IL (1) IL126590A (fr)
IS (1) IS2301B (fr)
MA (1) MA26427A1 (fr)
ME (1) ME00901B (fr)
MY (1) MY128051A (fr)
NO (1) NO312513B1 (fr)
NZ (2) NZ508303A (fr)
OA (1) OA10908A (fr)
PL (1) PL188164B1 (fr)
PT (1) PT904273E (fr)
SI (1) SI0904273T1 (fr)
SK (1) SK282674B6 (fr)
TN (1) TNSN97073A1 (fr)
TR (1) TR199802241T2 (fr)
TW (1) TW427989B (fr)
UA (1) UA47467C2 (fr)
UY (1) UY24543A1 (fr)
WO (1) WO1997042190A1 (fr)
YU (1) YU49398B (fr)
ZA (1) ZA973875B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
EP0985414B1 (fr) * 1998-05-26 2003-08-27 Pfizer Products Inc. Médicament pour le traitement du glaucôme et de la rétinopathie ischémique
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP1712222A3 (fr) 1999-12-23 2012-06-20 Pfizer Products Inc. Compositions pharmaceutiques fournissant des concentrations de médicaments améliorées
NZ551012A (en) * 2000-06-02 2008-04-30 Pfizer Prod Inc Use of S-methyl-dihydro-ziprasidone administered via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal or topical routes in doses ranging from 0.5 to 500 mg per day
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
WO2004050655A1 (fr) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Formes polymorphes de ziprasidone et son chlorhydrate
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
EP1633360A1 (fr) * 2003-05-16 2006-03-15 Pfizer Products Incorporated Traitement de troubles psychotiques et depressifs
EP1633361A1 (fr) * 2003-05-16 2006-03-15 Pfizer Products Inc. Traitements de l'angoisse avec la ziprasidone
CA2625837A1 (fr) * 2003-05-16 2004-11-25 Pfizer Products Inc. Procede pour ameliorer les fonctions cognitives en administrant du ziprasidone
CA2528100A1 (fr) * 2003-06-03 2005-04-21 Teva Pharmaceutical Industries Ltd Formes polymorphes de ziprasidone chlorhydrate et procedes pour leur elaboration
EP1663166A2 (fr) * 2003-09-02 2006-06-07 Imran Ahmed Formes posologiques a liberation prolongee de ziprasidone
US7667037B2 (en) * 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
CN1934108A (zh) * 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
EP1863806A1 (fr) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Ziprasidone mesylate amorphe
EP1855651A4 (fr) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Compositions nanoparticulaires de derives d'amide heterocyclique
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
EP1858892A1 (fr) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Mesylate de ziprasidone anhydre et son procede de preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
AU730856B2 (en) 2001-03-15
HU229057B1 (en) 2013-07-29
EG24401A (en) 2009-04-29
CN1092658C (zh) 2002-10-16
IS2301B (is) 2007-10-15
HUP9902808A2 (hu) 2000-03-28
GT199700042A (es) 1998-10-02
EP0904273A1 (fr) 1999-03-31
HRP970235A2 (en) 1998-06-30
NZ332219A (en) 2005-02-25
UA47467C2 (uk) 2002-07-15
IL126590A0 (en) 1999-08-17
EA199800909A1 (ru) 1999-04-29
AP9700978A0 (en) 1997-07-31
MA26427A1 (fr) 2004-12-20
TW427989B (en) 2001-04-01
SK150598A3 (en) 2000-03-13
HRP970235B1 (en) 2002-08-31
CZ349498A3 (cs) 1999-09-15
HUP9902808A3 (en) 2000-04-28
WO1997042190A1 (fr) 1997-11-13
NO985193L (no) 1998-11-06
PL329880A1 (en) 1999-04-12
HN1997000040A (es) 1997-06-05
KR100333214B1 (ko) 2002-06-20
AP838A (en) 2000-05-03
CZ289216B6 (cs) 2001-12-12
OA10908A (en) 2001-10-26
AU1936897A (en) 1997-11-26
NZ508303A (en) 2001-07-27
ZA973875B (en) 1998-11-06
YU49398B (sh) 2005-11-28
NO312513B1 (no) 2002-05-21
DE69720719T2 (de) 2003-11-06
US6110918A (en) 2000-08-29
PT904273E (pt) 2003-06-30
IL126590A (en) 2001-11-25
BG102893A (en) 1999-09-30
ES2192264T3 (es) 2003-10-01
CN1216990A (zh) 1999-05-19
AU730856C (en) 2001-11-15
DK0904273T3 (da) 2003-07-07
ME00901B (me) 2005-11-28
SI0904273T1 (en) 2003-08-31
IS4878A (is) 1998-10-23
YU17397A (sh) 2000-10-30
HK1017893A1 (en) 1999-12-03
ID17504A (id) 1998-01-08
UY24543A1 (es) 2000-09-29
BR9708932A (pt) 1999-08-03
ATE236902T1 (de) 2003-04-15
EP0904273B1 (fr) 2003-04-09
JPH11509865A (ja) 1999-08-31
SK282674B6 (sk) 2002-11-06
PL188164B1 (pl) 2004-12-31
DZ2221A1 (fr) 2002-12-03
CA2252895C (fr) 2002-08-20
EA001180B1 (ru) 2000-10-30
CA2252895A1 (fr) 1997-11-13
MY128051A (en) 2007-01-31
CO4940465A1 (es) 2000-07-24
DE69720719D1 (de) 2003-05-15
NO985193D0 (no) 1998-11-06
AR007003A1 (es) 1999-10-13
TR199802241T2 (fr) 1999-02-22
BG63601B1 (bg) 2002-06-28
KR20000010822A (ko) 2000-02-25
JP3102896B2 (ja) 2000-10-23

Similar Documents

Publication Publication Date Title
TNSN97073A1 (fr) Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1- piperazinyl)-etyl)-6-chloro-1,3-dihydro-2 h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant
TNSN97074A1 (fr) Dihydrates de mesylate de 5 - (2 - (4 - (1,2 - benzisothiazole - 3 - yl) - 1 - piperazinyl) ethyl) - 6 - chloro - 1,3 - dihydro - 2h - indole - 2 - one.
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
IL106777A (en) Monohydrate of 5-(2-(4-(1, 2-benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6- chloro-1, 3-dihydro-2h- indole-2-one hydrochloride and pharmaceutical compositions comprising it
NO20032161L (no) Tetrahydrobenzazepinderivater for anvendelse som modulatorer av dopamine D3-reseptor (antipsykotiske midler)
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
NL300175I1 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
ATE334973T1 (de) Chinazolinverbindungen
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
ES2147399T3 (es) Nuevos derivados de 2,3,5-trimetil-4-hidroxianilidas, su preparacion y su aplicacion terapeutica.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
TNSN99221A1 (fr) Derive d'indole nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant
PT790236E (pt) Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
TNSN00103A1 (fr) Formes cristallines nouvelles d'un antibiotique macrolide, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00105A1 (fr) Derives de 1-trifluoromethyl-4-hydroxy-7-piperidinyl- aminomethylchromane, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26075A1 (fr) Procede pour le traitement d'huile usagee.
TNSN00142A1 (fr) Complexe d'eletriptan et d'une sulfobutylether- betacyclodextrine, procede pour sa preparation et compositions pharmaceutiques les contenant.
TNSN00095A1 (fr) Benzolactames et thioamides cycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99104A1 (fr) 3 - cetoderives tricycliques de 6 - 0 - methylerythromycine, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01152A1 (fr) (7-(3-carboxyphenyl)-4-chloro-isoquinoleine-l-yl) guanidine, procede pour sa preparation et compositions la contenant.